(Bloomberg) — US regulators have refused to review Moderna Inc.’s novel mRNA flu vaccine, dealing a major blow to the company as it seeks more products beyond its Covid shot. Read More
Source link
Why a 25% discount on airline tickets wound up costing a Montreal couple more
When Air Canada announced a 25 per cent discount on base fares earlier this month, Dan Pomerantz and Melanie Lyman-Abramovitch thought they were in for a deal. Just 15 hours…







